Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Pharmacology

Background:

• A previous study identified anthraquinone analog BW-AQ-101 as a potent inducer of MDM2 degradation.
• BW-AQ-101 treatment led to p53 upregulation, apoptosis in cell cultures, and complete remission in acute lymphocytic leukemia (ALL) animal models.

Purpose of the Study:

• To systematically investigate the structure-activity relationship (SAR) of anthraquinone analogs.
• To identify novel analogs with improved or comparable potency to BW-AQ-101 for ALL treatment.

Main Methods:

• Synthesized and evaluated thirty-two anthraquinone analogs.
• Assessed cytotoxicity in two leukemia cell lines.
• Verified the effect of potent compounds on the MDM2-p53 axis using Western-blot assays.

Main Results:

• Identified several anthraquinone analogs with comparable or superior potency to BW-AQ-101.
• Confirmed the mechanism of action involving MDM2 degradation and p53 upregulation for potent analogs.
• Established SAR for the anthraquinone scaffold, guiding future optimization.

Conclusions:

• The study identified novel anthraquinone analogs as promising candidates for ALL therapy.
• These findings expand the chemical space for developing more effective MDM2-targeting agents.
• Further optimization of these analogs holds potential for improved cancer treatments.